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walked, and total time walked. Univariate and multivariate methods were used to assess the correlation between ambulation and type D personality.
Results: Seventy-one patients were enrolled with a mean age of 62.5 6 1.14 years and mean ABI of 0.55 6 0.03. Mean distance to symptoms, and total distance walked were 83.7 6 80.1 m, and 206.5 6 126.3 m, respectively. There were no significant correlations between the type D group and the questionnaires assessing psychosocial factors and perception of disease severity. At 6MWT, 83.1% of the patients developed symptoms, and 57.4% quit because of symptoms. Type D personality was present in 29.6% of the population (study, n ¼ 21). Compared with the nontype D population (control, n ¼ 50), there were no differences in demographic factors, comorbidities, or baseline ABI. Univariate analysis of objective measures of ambulation (Table) demonstrate statistically significant lower distance to symptoms in the study group, and trends toward lower total distance walked and quitting the 6MWT. A logistic regression model for patients who quit the 6MWT found that the study group had increased odds of quitting (OR 7.71; P ¼ 0.009) when controlling for confounders. A multiple linear regression model for total distance walked showed that the study group walked an average of 33.2 6 13.3 meters less than the control group (P ¼ .016) when controlling for confounding variables.
Conclusions: Despite equivalent demographics, comorbidities, baseline ABI, and perception of disease severity, the study group was limited in ambulation distance and more likely to quit the 6MWT. These data suggest that personality type is a strong predictor of disease impact in patients with IC. Further study is needed regarding progression of disease and response to treatment based on type D personality. Objectives: Chronic mesenteric ischemia (CMI) is an uncommon disease caused by stenosis or occlusion of one or more visceral arteries. Open repair (OR) has been the treatment of choice for many years, but endovascular repair (EV) has been increasingly utilized with good shortterm results. Unfortunately, there is no level-1-evidence that compares these two major treatment modalities for the treatment of CMI, and there are no clear guidelines on management strategies. In this study, we utilized a decision analysis model to evaluate the different interventions.
Methods: A Markov-state transition model was developed using TreeAge Pro 2012 (TreeAge Inc, Williamstown, Mass) to simulate a hypothetical cohort of 10,000 65-year-old female patients with CMI requiring treatment with either OR or EV. Data and probabilities to populate the decision model, including perioperative mortality risks, complication-, reintervention-, and patency rates and disease-specific mortality, were retrieved from original and systematic reviews for CMI. Costs were retrieved using the 2013 Medicare database. Outcomes evaluated were quality-adjusted life years (QALYs), total expected lifetime costs and an incremental costeffectiveness ratio (ICER) evaluated from the healthcare perspective. Extensive sensitivity analyses were performed for different clinical scenarios and probabilistic sensitivity analysis was performed to assess robustness of the model.
Results: For 65-year-old female patients with CMI and an average risk for operation, EV is slightly preferred with 10.24 expected QALYs (95% confidence interval [CI], 9.98-10.40) vs 9.93 QALYs (95% CI, 9.64-10.19) for OR. The difference between the two strategies is comparable to 4 months in perfect health (0.31 QALYs; 95% CI, 0.06-0.56). Sensitivity analysis shows that the younger the patient, the greater the difference in effectiveness in favor of EV: 0.4 QALYs (at 50 years) to 0.1 QALYs (at 95 years). Total expected reinterventions/patient are 1.56 for EV vs 0.28/patient in the OR group. At every age group, the number of expected reinterventions is around five times higher for patients initially treated with EV. Total expected costs for the reference-case patient are $48,440 6 $8,665 for OR and $43,099 6 $5,998 for EV. For patients between 50 years and 55 years old, EV is more expensive compared with OR but the incremental cost-effectiveness ratio for EV is under the willingness-to-pay threshold of $60,000/QALY. After the age of 55, costs for OR are higher and effectiveness is lower, and therefore OR is dominated by EV.
Conclusions: The results of this decision analysis suggest that EV is slightly favored for patients with CMI. Effectiveness of EV compared with OR is always higher for every age group and risk profile. Although EV has up to five times more expected reinterventions, EV appears to be cost-effective for all patient groups. Decision analysis provides a useful means to monitor outcomes and cost-effectiveness of different treatment options. Objectives: Carotid artery stenting (CAS) can offer advantages over carotid endarterectomy (CEA) in certain patient populations, such as those with hostile necks. However, CEA and CAS are fundamentally different. CAS routinely covers the external carotid artery (ECA), and we hypothesize that this increases the risk of ECA occlusion. Since the ECA can be an important source of cerebral blood flow in cases of high-grade internal carotid artery stenosis or occlusion, ECA occlusion may be important to long-term cerebral perfusion. Furthermore, CAS causes disturbed flow into the ECA that likely promotes ECA stenosis and may contribute to in-stent restenosis (ISR). Our objective was to identify whether CAS increased the rate of external carotid artery occlusion, and whether ECA occlusion was associated with in-stent restenosis.
Carotid Artery Stenting Has
Methods: Patients undergoing CAS or CEA from February 200 to February 2012 with follow-up carotid ultrasounds in our system were 
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